Drug Trial Radar · NCT00153101
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Last checked: Nov 19, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31,546
Actual
Start
Nov 2001
Primary completion
Jun 2008
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Model
- Parallel
- Primary purpose
- Prevention
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Conditions
- Cardiovascular Diseases
Interventions
TelmisartanDrug
Combination of Telmisartan and RamiprilDrug
RamiprilDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart FailureTime frame: 56 months
- ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy PatientsTime frame: 56 months
- TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart FailureTime frame: 56 months
Locations
732 sites in 41 countries. Site status is shown where the registry gives one.
502.373.0256 Boehringer Ingelheim Investigational Site
Athens, Alabama
502.373.0251 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
502.373.0182 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
502.373.0188 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
502.373.0189 Boehringer Ingelheim Investigational Site
Tucson, Arizona
502.373.0177 Boehringer Ingelheim Investigational Site
Tuscon, Arizona
502.373.0209 Boehringer Ingelheim Investigational Site
Bentonville, Arkansas
502.373.0173 Boehringer Ingelheim Investigational Site
Concord, California
502.373.0266 Boehringer Ingelheim Investigational Site
Harbor City, California
502.373.0283 Boehringer Ingelheim Investigational Site
Loma Linda, California
502.373.0180 Boehringer Ingelheim Investigational Site
Los Angeles, California
502.373.0175 Boehringer Ingelheim Investigational Site
Sacramento, California
502.373.0165 Boehringer Ingelheim Investigational Site
San Diego, California
502.373.0228 Boehringer Ingelheim Investigational Site
San Leandro, California
502.373.0205 Boehringer Ingelheim Investigational Site
Sylmar, California
502.373.0277 Boehringer Ingelheim Investigational Site
West Hills, California
502.373.0226 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut
502.373.0174 Boehringer Ingelheim Investigational Site
Farmington, Connecticut
502.373.0258 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
502.373.0179 Boehringer Ingelheim Investigational Site
Gainesville, Florida
502.373.0183 Boehringer Ingelheim Investigational Site
Palm Harbor, Florida
502.373.0240 Boehringer Ingelheim Investigational Site
Panama City, Florida
502.373.0171 Boehringer Ingelheim Investigational Site
Tampa, Florida
502.373.0282 Boehringer Ingelheim Investigational Site
Vero Beach, Florida
502.373.0214 Boehringer Ingelheim Investigational Site
Weston, Florida
502.373.0161 Boehringer Ingelheim Investigational Site
Augusta, Georgia
502.373.0193 Boehringer Ingelheim Investigational Site
Augusta, Georgia
502.373.0201 Boehringer Ingelheim Investigational Site
Augusta, Georgia
502.373.0223 Boehringer Ingelheim Investigational Site
Conyers, Georgia
502.373.0268 Boehringer Ingelheim Investigational Site
Sandersville, Georgia
502.373.0245 Boehringer Ingelheim Investigational Site
Savannah, Georgia
502.373.0199 Boehringer Ingelheim Investigational Site
Tucker, Georgia
502.373.0162 Boehringer Ingelheim Investigational Site
Valdosta, Georgia
502.373.0203 Boehringer Ingelheim Investigational Site
Pocatello, Idaho
502.373.0244 Boehringer Ingelheim Investigational Site
Burbank, Illinois
502.373.0272 Boehringer Ingelheim Investigational Site
Chicago, Illinois
502.373.0217 Boehringer Ingelheim Investigational Site
Olympia Fields, Illinois
502.373.0270 Boehringer Ingelheim Investigational Site
Des Moines, Iowa
502.373.0167 Boehringer Ingelheim Investigational Site
Monroe, Louisiana
502.373.0158 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
Showing 40 of 732 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.